SUCCESS: Series of Unique Creative Continuing Education Self Studies

You are not logged in. (Login)


IgG Structure and Function
Effect on Hemolytic Disease of the Newborn and Neonatal Alloimmune Thrombocytopenia Severity
(Release Date: 05/07/2018) Hemolytic Disease of the Newborn (HDN) and Neonatal Alloimmune Thrombocytopenia (NAIT) pose significant morbidity and mortality risk.  Prevention and early detection are key.  Recent studies have described a correlation between immunoglobulin structure and clinical severity.  Typical IgG structure and immunoglobulin structural alterations along with the study results will be presented.

Indications for Transfusion (Release Date: 06/14/2017) Indications are established reasons for transfusion, which will benefit the patient. However blood components are drugs and can have adverse effects and should not be administered indiscriminately. This course will highlight the main indications and some of the adverse effects that can occur with the transfusion of red blood cells, plasma, and platelets.

Group AB Plasma and the Risk of TRALI (Release Date: 2/20/2012)
This presentation begins with two case reports of fatal TRALI, followed by a discussion of TRALI diagnosis and pathogenesis. The role of group AB plasma in these reactions is outlined and recommendations that hospitals restrict group AB plasma use to those patients who absolutely require it are explained in detail.

Transfusion Management of the IgA-Deficient Patient (Release Date: 10/01/2009)
The laboratory evaluation and transfusion management of IgA-deficient individuals, who may or may not have a history of prior anaphylaxis, is reviewed. American Rare Donor Program blood product release criteria and blood product selection are also discussed.

What's New with Granulocyte Transfusions (Release Date: 07/01/2009)
Issues related to granulocyte transfusions are reviewed, including indications for transfusion, ordering products and administration. Product-related issues including regulations, product dose and donor safety are covered. Future research efforts are highlighted. NOTE: when you review the lecture on granulocytes, you will see references to the RING Study. This study was designed to test the efficacy of high doses of granulocytes and antimicrobial therapy compared to antimicrobial therapy alone in neutropenic patients. The study failed to accrue the targeted number of patients and closed in 2014. There was no difference between the two groups, but because of the low accrual, the study was under-powered.

Adverse Reactions to Transfusion (Release Date: 09/10/2014) Some adverse reactions are preventable but many cannot currently be anticipated or avoided. Prompt recognition of suspected reactions and cessation of transfusion limit their severity and can prevent fatalities. This course provides an overview of adverse transfusion reactions and reviews steps to prevent them or limit their severity.

Clinical Case conference: Autoimmune hemolytic anemia (Release Date: 04/10/2015) Anemia can result from different causes and and correctly diagnosing its source can be challenging. Transfusion therapies that will result in successful clinical management of anemia require correct laboratory diagnosis. Prompt recognition of suspected reactions and cessation of transfusion limit their severity and can prevent fatalities. This course provides an overview of adverse transfusion reactions and reviews steps to prevent them or limit their severity.

Septic Transfusion Reactions: Lessons from the Headlines and Hemovigilance (Release date: 12/07/2015) Septic reactions from apheresis platelet transfusion are a leading cause of morbidity and mortality, but there are opportunities to increase awareness, recognition and reporting that could improve safety for patients.

Practical Coagulation for the Blood Bank (Release date: 06/30/2016) This course provides a summary of the general coagulation model which includes initiation, amplification and propagation. There is also a look at thrombin’s role in clot formation as well as a review of the common coagulation tests and the major drugs used in coagulation abnormalities.

An Introduction to Pathogen Reduction (Release date: 08/31/2016) This course defines the concept of pathogen reduction, describes the pathogen reduction systems available for blood components and summarizes the studies conducted to date.

FDA Draft Guidance on Platelet Safety (release date: 09/19/2017) This course reviews the significant elements of the FDA Draft Guidance on mitigation of bacterial contamination in platelets. This learning material also identifies the challenges for implementation of the proposed process changes and addresses how the Final Guidance may appear after public comments have been submitted and reviewed.

CEU Course: FDA Draft Guidance on Platelet Safety

Platelets play a vital role for all transfusion services. However there are risks associated with their use, in particular the possibility of bacterial contamination. In light of this, in March of 2016 the FDA released draft Guidance proposing measures to increase platelet safety. This course provides an overview of the Guidance and highlights some of the challenges to implementation.

Technologists, Technicians, Laboratory Managers
There are no participant prerequisites for this activity.

Enter Course

At the conclusion of this activity, participants should be able to:

  1. Be familiar with the significant elements of the draft Guidance.
  2. Identify the challenges in implementing the suggested process changes.
  3. Discuss how the final Guidance may appear after public comments have been submitted.

To receive CEU credit for this activity, participants must:

  1. Review the presentation "Indications for Blood Transfusion" or review the slides and accompanying notes available as a printable Adobe Reader® file.
  2. Take the online Post-Test.
  3. Complete the online Activity Evaluation.
  4. Print the certificate awarding 1.0 CEU through the SUCCESSTM program.

Catherine Mazzei, MD
Medical Director, Northern California Region
American Red Cross

Catherine Mazzei, MD
Medical Director, Northern California Region
American Red Cross


Listed in the presentation.

Activity faculty and planners have indicated that they have no relevant financial relationships with commercial interests to disclose. No commercial support was received for this activity.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American Red Cross Biomedical Services. Information herein is presented for educational purposes only and not to endorse off-label use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The American Red Cross Biomedical Services designates this educational activity for a maximum of 1.0 CEU credit; students should only claim credit commensurate with the extent of their participation in the activity.

If you correctly answer 70% or more of the post-test items you may claim credit.

All faculty participating in ARCBS continuing medical education programs are expected to disclose to learners whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s); faculty are also expected to disclose off-label and/or investigational uses of products under discussion.

RELEASE DATE: 09/20/2017